高原
发表时间:2020-03-28 阅读次数:248次

 

 

姓      名

 高原

性      别

 女

职      称

 副研究员

学      历

 博士

电      话

 021-51980025

传      真

 

电子邮件

 yuan_gao@fudan.edu.cn

个人主页

 

通讯地址

 上海浦东张衡路826号科研楼东辅楼201室,邮编:201203
 

副研究员,医学博士,1995、1998年先后在沈阳药科大学获得药剂学学士和硕士学位,2009年毕业于第二军医大学,2010-2012先后在中科院药物所、加拿大Alberta大学开展博士后研究。曾在上药集团、第二军医大学长海医院从事新药研发和基础医学转化研究,也曾在国家药品监督管理局新药审评中心进修。2017年加入复旦大学药学院。主要研究方向为:1)药品注册相关法规研究及实践;2)药物精准治疗的研究及转化。

 

科研成果
 
1. 项目与专著

近年来主持国家自然基金面上项目 “基于肿瘤免疫-基因联合治疗策略的间充质干细胞仿生纳米递送系统抑制去势抵抗性前列腺癌的作用机制研究(81972392)”和“CG3适体介导的肿瘤环境响应性纳米胶束载miR-26a/恩扎鲁胺靶向去势抵抗性前列腺癌的作用机制研究(81672545)”;上海市卫健委临床研究专项“基于细胞治疗临床试验的风险识别与模型构建(201840306)”;上海市医院药学研究基金“粘膜下肿瘤标记用三嵌段温敏凝胶的应用”。主编《滴眼剂的开发与生产》、《药物制剂生产工艺与注解》专著2本。

2. 论文

1) Chen J, Wu Z, Ding W, Wu W, Gao S, Cai W*, Gao Y*. SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer. Theranostics, doi:10.7150/thno.40489 (2020) (IF 8.063).

2)Jiang W#, Chen J#, C Gong, Y Wang, Gao Y*, Y Yuan*. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy. J Nanobiotech (2020) DOI: 10.1186/s12951-020-00607-4. (IF 5.35).

3) Wang X#, Gao Y#, Yang Y#, Liu Z, Gao L, Wu F, Yang X, Xu X, Wang Z*, Sun S*. Validation and evaluation of a newly developed time-resolved fluoroimmnoassay for cyclosporine quantitative analysis in human whole blood. J Pharm Biomed Analysis. 177(2020), 112870. (IF2.98)

4) Li G#, Gao Y#, Gong C#, Han Z, Qiang L, Tai Z, Tian J, Gao S*. Dual-blockade immune checkpoint for breast cancer treatment based on a tumor-penetrating peptide assembling nanoparticle. ACS Applied Materials & Interfaces 2019, 11, 43, 39513-24 (IF=8.456).

5) Wu W#, Tang Z#, Chen J, Gao Y*, Pediatric drug development in China: Reforms and challenges. Pharmacological Research, 148(2019)104412 (IF 5.57)

6) Qiang L, Cai Z, Jiang W, Liu J, Tai Z, Li G, Gong C, Gao S*, Gao Y*. A novel macrophage-mediated biomimetic delivery system with NIR-triggered release for prostate cancer therapy. J Nanobiotech (2019) https://doi.org/10.1186/s12951-019-0513-z (IF=5.345).

7) Li Y, Gao Y#, Gong C#, Xia Q, Gu F, Hu C, Zhang L, Guo H*, Gao S*. A33 antibody-functionalized Exosomes for Doxorubicin Delivery Against Colorectal Cancer. Nanomedicine: Nanotechnology, Biology, and Medicine. 14(7):1973-85 (2018) (IF=6.5).

8) Xia Q, Gong C, Gu F, Wang Z, Hu C, Zhang L, Qiang L, Ding X, Gao S*, Gao Y*. Functionalized Multi-walled Carbon Nanotubes for Targeting Delivery of Immunostimulatory CpG Oligonucleotides Against Prostate Cancer. J. Biomed. Nanotechnology. 14: 1-14 (2018) (IF=5.09).

9) Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L, Qiang L, Gao S*, Gao Y*. Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. J Control Release 266, 272-286 (2017) (IF=7.901).

10) Gu F, Hu C, Tai Z, Yao C, Tian J, Zhang L, Xia Qing, Gong C, Gao Y*, Gao S* Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer. Scientific Reports 6: 36281(2016).

11) Gao Y, Sarfraz M, Roa W, Clas S-D, Lobenberg R*. Hyaluronic acid–tocopheryl succinate micelles containing rifampicin for active targeting to macrophages. J. Biomed. Nanotechnology. 11: 1-18 (2015).

12) Yao C, Tai Z, Wang X, Liu J, Quan G, Wu X, Zhang L, Zhang W, Gao Y*, Gao S*. Reduction-responsive cross-linked stearyl peptide for effective delivery of plasmid DNA. Int J Nanomedicine. 10: 3403–16 (2015).

13) Gao Y, Zuo J, Bou-Chacra N, Pinto T, Clas S, Walker R, Lobenberg R*. In vitro release kinetics of anti- tuberculosis drugs from nanoparticles assessed using a modified dissolution apparatus. Biomed. Res. Inter. http://dx.doi.org/10.1155/2013/136590(2013).

14) Gao Y, Ren FZ, Ding BY, Sun NY, Liu X, Ding XY, Gao S*. PLGA–PEG–PLGA-based hydrogel for sustained release of docetaxel. J. Drug Targeting 19: 516-27 (2011).

15) Gao Y, Sun Y, Ren FZ, Gao S*. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate. Drug Dev. Ind. Pharm. 36: 1131–8 (2010).

 

 

3.授权专利

1. CN101134036A含有雷贝拉唑和碳酸氢钠的制剂及其制备方法,2013.12授权

2. CN101444521B 包含阿仑膦酸钠和胆维丁的药物制剂, 2012.7授权

 

 

 

Copyright 2012 复旦临床药学网 技术支持:维程互联

网站访问量: